# Dose Tapering Study of Adalimumab in Psoriasis

> **NCT04028713** · PHASE4 · TERMINATED · sponsor: **University Hospital, Ghent** · enrollment: 19 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **PROCEDURE:** Venapuncture
- **PROCEDURE:** Dried blood spot
- **DRUG:** Dose reduction

## Key facts

- **NCT ID:** NCT04028713
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-16
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-03-22
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Too slow inclusion rate.
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04028713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04028713, "Dose Tapering Study of Adalimumab in Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04028713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*